Clinical trial Recruiting at 1 site Observational Ages 18 and up

High-risk plaque on photon-counting CT and future coronary events

Official title: Prognostic Value of Photon-Counting Detector CT-Derived High-Risk Coronary Plaque Features for Predicting Major Adverse Cardiovascular Events: a Prospective Cohort Study

Run by Beijing Chao Yang Hospital · NCT07822737 · Data updated 2026-11-12

This study tests whether high-risk plaques seen on photon-counting CT can predict future major heart events in people with coronary disease.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment500 (estimated)
SponsorBeijing Chao Yang Hospital
Academic / other
Locations1 site (Beijing, China)
StatusRecruiting
StartedJanuary 18, 2025
Main results expectedDecember 30, 2028
Study endsDecember 30, 2030
Registry record updatedSeptember 16, 2026
Trial IDNCT07822737 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older with acute or stable coronary syndromes scheduled for non-emergent invasive angiography and OCT evaluation.

Probably not a fit

Patients without detectable PCCT-defined high-risk plaque features or those unlikely to experience events based on other risk factors may see limited benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-center observational study enrolls adults with acute or stable coronary syndromes who are planned for invasive angiography and OCT. Participants undergo a contrast-enhanced photon-counting detector CT to identify high-risk plaque features, and within about 30 days have invasive angiography with OCT for cross-sectional comparison. The study assesses whether PCCT-detected high-risk plaque predicts major adverse cardiovascular events or revascularization during follow-up, and compares PCCT findings with OCT results using blinded core laboratories. Data from the imaging modalities will be analyzed to evaluate diagnostic performance relative to clinical outcomes. The overall goal is to determine if non-invasive PCCT can help identify patients at higher risk for future events.

Why it matters

Potential benefit: If successful, PCCT could help identify patients at higher risk for future heart events using a non-invasive test.

How similar studies have gone: Previous imaging studies show promise linking plaque features to risk, but direct use of PCCT-defined high-risk plaque to predict events is still being established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥18 years
* Scheduled for clinically indicated, non-emergent invasive coronary angiography
* Provision of written informed consent and willingness to comply with long-term follow-up

Exclusion Criteria:

* Estimated glomerular filtration rate \<45 mL/min/1.73 m²
* Known allergy to iodinated contrast media
* Pregnancy or breastfeeding
* Persistent atrial fibrillation or other arrhythmia precluding adequate ECG-gated CT acquisition
* Body mass index \>40 kg/m²
* Target vessel with a previously implanted stent
* Life expectancy \<2 years or any condition that, in the opinion of the investigator, makes follow-up unlikely or participation inappropriate

Where it's running

  • Beijing Chaoyang Hospital,Capital Medical University, Beijing
    Beijing, China, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.